This election season, California voters are considering Proposition 38, a ballot measure that would authorize $8.4 billion in state bonds for immunology and immunotherapy research at California ...
Tavapadon (Juvmo) is a new once-daily pill for Parkinson’s motor symptoms. Here’s how it works, who it may help and what to ...
NEW YORK, NY – July 13, 2026 – The Alzheimer’s Drug Discovery Foundation’s (ADDF) Diagnostics Accelerator (DxA) and The Michael J. Fox Foundation (MJFF) today announced a new $5 million partnership to ...
Variations in the LRRK2 gene are one of the strongest known genetic contributors to Parkinson’s. These variations cause overactivity in the LRRK2 protein pathway that ultimately damages dopamine ...
NEW YORK, May 5, 2026 /PRNewswire/ — The Michael J. Fox Foundation for Parkinson’s Research (MJFF), which sponsors the landmark Parkinson’s Progression Markers Initiative (PPMI), today announced the ...
A stem cell-based dopamine neuron replacement therapy for the treatment of motor symptoms in Parkinson’s disease (PD) has received conditional, limited approval for use in Japan, a first for this type ...
For people living with Parkinson’s disease — and for the families, friends and care partners who love them — progress depends not only on scientific discovery but also the public policies that help ...
“One of the things I’m most happy about, with all the things I’ve done over the past 25 years, is helping take the shame out of having Parkinson’s. There used to be a lot of shame, for whatever reason ...
A new drug application (NDA) has been submitted to the U.S. Food and Drug Administration (FDA) for tavapadon, a once-daily, oral treatment for the tremors, slowness and stiffness — referred to as ...
The maker of prasinezumab announced this week that the drug is moving into the critical, Phase III stage of clinical trials. If successful, the trial’s findings ultimately could be used to request ...
The U.S. Food and Drug Administration (FDA) will be re-reviewing ND0612, a 24-hour, under-the-skin infusion of liquid levodopa/carbidopa, with a decision expected by the end of 2025. ND0612 previously ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results